Literature DB >> 30948156

Induction of human pluripotent stem cell-derived natural killer cells for immunotherapy under chemically defined conditions.

Hiroyuki Matsubara1, Akira Niwa2, Tatsutoshi Nakahata3, Megumu K Saito4.   

Abstract

Natural killer (NK) cells are innate lymphocytes and show cytotoxicity against tumor cells without prior antigen specific stimulation. Because of their innate properties, NK cells are being considered for immunotherapies against various malignancies or leukemia. Human pluripotent stem cells (hPSCs) are capable of inducing enough NK cells for allogeneic transplantation. However, current induction protocols require feeder cells or human or bovine serum for the differentiation and expansion of NK cells, which incurs potential risk for contamination and may cause lot dependency in the cells. To address these issues, here we established a differentiation protocol for developing functional NK cells from hPSCs under a completely chemically-defined condition. The resultant PSC-derived NK cells show comparable phenotypes to those produced under serum-containing condition, exerting strong killing potential against a leukemia cell line in vitro and resistance to tumor growth in vivo. Our protocol can be a useful tool for applying PSC-derived NK cells to future cellular cancer immunotherapies.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Clinical grade; Immunotherapy; Natural killer cell; Pluripotent stem cell

Mesh:

Year:  2019        PMID: 30948156     DOI: 10.1016/j.bbrc.2019.03.085

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  9 in total

Review 1.  Enhancing a Natural Killer: Modification of NK Cells for Cancer Immunotherapy.

Authors:  Rasa Islam; Aleta Pupovac; Vera Evtimov; Nicholas Boyd; Runzhe Shu; Richard Boyd; Alan Trounson
Journal:  Cells       Date:  2021-04-29       Impact factor: 6.600

Review 2.  Hematopoietic stem cell- and induced pluripotent stem cell-derived CAR-NK cells as reliable cell-based therapy solutions.

Authors:  Jonathan Arias; Jingwei Yu; Mukesh Varshney; Jose Inzunza; Ivan Nalvarte
Journal:  Stem Cells Transl Med       Date:  2021-02-26       Impact factor: 6.940

3.  High-Yield Human Induced Pluripotent Stem Cell-Derived Monocytes and Macrophages Are Functionally Comparable With Primary Cells.

Authors:  Di Cui; Alexandra Franz; Sophie A Fillon; Linda Jannetti; Timo Isambert; Katrin Fundel-Clemens; Heinrich J Huber; Coralie Viollet; Alexander Ghanem; Akira Niwa; Bernd Weigle; Stefan Pflanz
Journal:  Front Cell Dev Biol       Date:  2021-04-13

Review 4.  CAR-NK Cells: From Natural Basis to Design for Kill.

Authors:  Muhammad Babar Khawar; Haibo Sun
Journal:  Front Immunol       Date:  2021-12-14       Impact factor: 7.561

Review 5.  Prospects for Development of Induced Pluripotent Stem Cell-Derived CAR-Targeted Immunotherapies.

Authors:  Roberta Mazza; John Maher
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2021-12-12       Impact factor: 4.291

Review 6.  Taking Lessons from CAR-T Cells and Going Beyond: Tailoring Design and Signaling for CAR-NK Cells in Cancer Therapy.

Authors:  Katharina Eva Ruppel; Stephan Fricke; Ulrike Köhl; Dominik Schmiedel
Journal:  Front Immunol       Date:  2022-03-18       Impact factor: 7.561

Review 7.  Current Progress of CAR-NK Therapy in Cancer Treatment.

Authors:  Zhaojun Pang; Zhongyi Wang; Fengqi Li; Chunjing Feng; Xin Mu
Journal:  Cancers (Basel)       Date:  2022-09-02       Impact factor: 6.575

Review 8.  Optimizing NK Cell-Based Immunotherapy in Myeloid Leukemia: Abrogating an Immunosuppressive Microenvironment.

Authors:  Natasha Mupeta Kaweme; Fuling Zhou
Journal:  Front Immunol       Date:  2021-06-17       Impact factor: 7.561

9.  A novel CD2 staining-based flow cytometric assay for assessment of natural killer cell cytotoxicity.

Authors:  Dan Zhang; Rui Teng; Nan Lv; Lei Lei; Yanmeng Wang; Ramone A Williamson; Ping Chen; Peigen Gao; Michael O'Dwyer; Ang Li; Jinsong Hu
Journal:  J Clin Lab Anal       Date:  2020-08-17       Impact factor: 3.124

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.